|
| Press Releases |
|
 |
|
| Friday, May 27, 2022 |
|
|
Legend Capital's Portfolio Company Feima Robotics Assists China's 38th Antarctic Expedition with a Series of Civilian UAV Products |
| On April 26, 2022, the expedition ship Xuelong 2 for China's 38th Antarctic expedition berthed at the Shanghai base dock. So far, China's 38th Antarctic expedition, which lasted 174 days and traveled more than 33,000 nautical miles, has ended successfully. more info >> |
|
| Wednesday, April 27, 2022 |
|
|
Legend Capital's Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis |
| Legend Capital's portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. more info >> |
|
| Tuesday, April 26, 2022 |
|
|
Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022 |
| Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO) on the KOSDAQ market, and it plans to submit a registration statement within the second quarter of 2022. more info >> |
|
| Sunday, April 24, 2022 |
|
|
君联资本联合创建企业朗信生物遗传性视网膜变性基因治疗产品在中国获批临床 |
| 君联资本联合创建企业朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣布，公司产品LX101注射液用于治疗RPE65双等位基因突变相关的遗传性视网膜变性（IRD）患者的临床试验申请，已获得中国国家药品监督管理局药品审评中心（CDE）批准。 more info >> |
|
|
君聯資本聯合創建企業朗信生物遺傳性視網膜變性基因治療產品在中國獲批臨床 |
| 君聯資本聯合創建企業朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣佈，公司產品LX101注射液用於治療RPE65雙等位基因突變相關的遺傳性視網膜變性（IRD）患者的臨床試驗申請，已獲得中國國家藥品監督管理局藥品審評中心（CDE）批准。 more info >> |
|
|
Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China |
| Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics more info >> |
|
| Thursday, April 7, 2022 |
|
|
君联资本所投创新型疫苗领军企业瑞科生物在港交所成功上市 |
| 3月31日，君联资本所投创新型疫苗领军企业瑞科生物（股票代码：02179.HK）在港交所成功上市。此次在港上市，成为“香港HPV疫苗第一股”、“香港新型佐剂疫苗第一股”的瑞科生物相信将会给香港资本市场注入新的活力。 more info >> |
|
|
君聯資本所投創新型疫苗領軍企業瑞科生物在港交所成功上市 |
3月31日，君聯資本所投創新型疫苗領軍企業瑞科生物（股票代碼：02179.HK）在港交所成功上市。此次在港上市，成為「香港HPV疫苗第一股」、「香港新型佐劑疫苗第一股」的瑞科生物相信將會給香港資本市場注入新的活力。
more info >> |
|
|
Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully |
| On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. more info >> |
|
| Tuesday, March 8, 2022 |
|
|
从边缘走向舞台中央：君联资本所投生物技术产业链上游专精特新企业的奋斗之路 |
| 据联想控股微空间报导，「专精特新」的灵魂是创新，强调「专精特新」就是要鼓励创新。政策目标在于强化科技创新和产业链供应链韧性，加强基础研究，推动应用研究，开展补链强链专项行动，加快解决「卡脖子」难题。联想控股旗下君联资本不仅有幸参与到众多「专精特新」企业的发展中，也践行着将「前瞻性」及「硬科技」作为关键词的投资理念。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 23:00: JST
|
|
|
General MRO Aerospace 取得中國民航局認證，拓展全球維修能力
Mar 13, 2026 22:20 HKT/SGT
|
|
|
General MRO Aerospace 获得中国民航局认证，拓展全球维护能力
Mar 13, 2026 22:20 HKT/SGT
|
|
|
General MRO Aerospace Achieves CAAC Certification, Expanding Global Maintenance Capabilities
Mar 13, 2026 22:20 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 22:00 HKT/SGT
|
|
|
CITIC Resources Deepens Dual-Engine Strategy of 'Investment + Trading', Continues to Promote High-Quality Development
Mar 13, 2026 21:01 HKT/SGT
|
|
|
中信資源深化「投資+貿易」雙輪戰略 持續驅動高質量發展 推進「上游資產布局、貿易業務拓展、生產運營提質」
Mar 13, 2026 20:53 HKT/SGT
|
|
|
中信资源深化「投资+贸易」双轮战略 持续驱动高质量发展 推进「上游资产布局、贸易业务拓展、生产运营提质」
Mar 13, 2026 20:40 HKT/SGT
|
|
|
康哲藥業：腎性貧血新藥德昔度司他片中國獲批上市
Mar 13, 2026 20:24 HKT/SGT
|
|
|
康哲药业：肾性贫血新药德昔度司他片中国获批上市
Mar 13, 2026 20:15 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 18:00: JST
|
|
|
uSMART HK Expands to 12 Physical Service Centres in One Year, Accelerating "Online x Offline" O2O Community Finance Strategy
Mar 13, 2026 17:34 HKT/SGT
|
|
|
盈立證券一年拓展12個服務網點 全力深化「線上x線下」O2O社區金融佈局
Mar 13, 2026 17:21 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 17:00 HKT/SGT
|
|
|
盈立证券一年拓展12个服务网点 全力深化「在线x线下」O2O小区金融布局
Mar 13, 2026 16:56 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
